share_log

BioXcel Therapeutics Q1 2024 GAAP EPS $(0.87) Beats $(1.04) Estimate, Sales $582.000K Beat $464.000K Estimate

Benzinga ·  May 9 07:11

BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.04) by 16.35 percent. This is a 52.72 percent increase over losses of $(1.84) per share from the same period last year. The company reported quarterly sales of $582.000 thousand which beat the analyst consensus estimate of $464.000 thousand by 25.43 percent. This is a 182.52 percent increase over sales of $206.000 thousand the same period last year.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment